Phase 4 N=25 Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy
Nonproliferative Diabetic Retinopathy
Primary: The Best Corrected Visual Acuity (BCVA) — 67.6; 76.36 letters — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=81 Intrathecal Morphine Versus Epidural Extended Release Morphine for Pediatric Patients Undergoing Spinal Fusion
Pain Management · Spinal Fusion · Scoliosis
Primary: Total IV Morphine Consumption up to 48 Hours Post Surgery — 34.0; 42.2 mg — p=.27
Phase 2 N=13 High Protein Diet in Patients With Long-chain Fatty Acid Oxidation Disorders
Very Long-chain Acyl-CoA Dehydrogenase Deficiency · Trifunctional Protein Deficiency · Carnitine Palmitoyltransferase 2 Deficiency
Primary: Energy Expenditure — 2045; 2343 kcal
N/A N=50 A Pilot Study of Biomarkers in Obstructive Sleep Apnea
Obstructive Sleep Apnea
Primary: Serum IL-6 (Interleukin 6) Levels — NA; NA; NA pg/mL
N/A N=51 Evaluating and Improving Functional Driving Vision of Patients With Astigmatism: Phase 3
Astigmatism
Primary: Tactical Composite Score — 0.34; -0.01; -0.33 score on a scale
Phase 3 N=391 Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis
Dermatitis, Atopic
Primary: Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to (>=) 2 Points…
Phase 4 N=25 Study of Naltrexone-Induced Blockade of Antidepressant Effects
Depression · Major Depressive Disorder
Primary: BOLD Responses in the rACC Cortex During the Processing of Contextual Cues at Baseline (Post-placebo) — 0.47 BOLD signal — p=0.01
Phase 2 N=57 Prevention of Syncope Trial 6 - Atomoxetine in Vasovagal Syncope
Vasovagal Syncope
Primary: Number of Participants Who Become Syncopal Associated With Diagnostic Criteria of Hypotension and Bradycardia — 19; 10 Participants
N/A N=8 Balance Bike Training in Down Syndrome
Down Syndrome · Postural Balance
Primary: Pediatric Balance Scale (PBS) Mean Group Score — 48.43; 49.43 score on a scale — p=<0.05
Phase 3 N=606 A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
Constipation Predominant Irritable Bowel Syndrome
Primary: 6 of 12 Week Overall Responder Rate — 83; 56 Participants — p=<0.02
Phase 3 N=736 Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo
Axial Spondyloarthrithis · Ankylosing Spondylitis
Primary: Percentage of Participants in Part B Who Did Not Experienced a Flare — 20.2; 83.7; 79.0 percentage of participants — p=<0.001
Phase 3 N=196 Clinical Study to Evaluate the Efficacy and Safety of VR506 Using a New Inhaler for the Treatment of Asthma
Asthma
Primary: Mean Prednisone/Prednisolone Dose for Analysis (PDA) at End of Study (Week 16) — 4.55; 4.31; 3.97 mg — p=0.772
Phase 3 N=128 An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine
Migraine Disorder
Primary: Number of Participants With Any Treatment Emergent Adverse Events (TEAEs) — 91 Participants
Phase 3 N=303 Erlotinib Prevention of Oral Cancer (EPOC)
Oral Cancer
Primary: Oral Cancer-free Survival in Participants Receiving Erlotinib as Compared With the Control Arm or Placebo Group. — 55; 18 Participants
N/A N=103 Chronic Pain Skills Study - Vanderbilt University Medical Center
Chronic Pain
Primary: Change in Pain Intensity — 4.42; 6.625 units on a scale